BusinessVBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMay 1, 2018, 12:01 PM UTC
BusinessVBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) PatientsBy Nasdaq OMXApr 17, 2018, 12:01 PM UTC
BusinessVBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901By Nasdaq OMXJan 17, 2018, 1:00 PM UTC
BusinessVBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceBy Nasdaq OMXDec 12, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017By Nasdaq OMXNov 10, 2017, 1:00 PM UTC
BusinessVBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 MillionBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessVBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 MillionBy Nasdaq OMXOct 26, 2017, 1:29 PM UTC
BusinessVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common SharesBy Nasdaq OMXOct 25, 2017, 8:01 PM UTC
